Consistently taking pre-exposure prophylaxis (PrEP) reduces the risk of acquiring HIV by almost 90%. Washington, DC has a high incidence of HIV (360 new cases in 2018) which disproportionately affects people of color (71.1% Black and 9.2% Latinx). The DC Health and Wellness Center began prescribing PrEP in 2016 to start and maintain men who have sex with men (MSM) and transgender women of color on PrEP at low or no cost to them. We assessed differences between patients on PrEP <1 month and those on ≥1 month.
Demographics and reasons for starting PrEP were collected in REDCap at initiation. Eligible patients received PrEP, scheduled a follow-up visit, and agreed to additional follow-ups every 3 months. REDCap data were merged with medical records to determine time on PrEP. Chart reviews were done to establish duration of therapy. Patients taking PrEP <1 month and ≥1 month were compared using chi-square analysis and multivariate logistic regression to explore the associations of race/ethnicity, age, gender identity, and insurance status.
From August 2016 – December 2018, 530 people were prescribed PrEP; 81.7% were people of color (47.2% Black, 28.5% Latinx, and 6.0% other), 80.2% were MSM, 10.0% were cisgender women, and 3.6% were transgender women. Of these, 280 (52.8%) were still on PrEP at ≥1 month and 250 (47.2%) were not. Likelihood of being on PrEP ≥1 month increased with age (AOR: 1.02, 95% CI 1.00-1.04). Patients on PrEP ≥1 month were less likely to be transgender women (AOR: 0.089, 95% CI 0.019-0.41) or cisgender women (AOR: 0.21, 95% 0.095-0.46) compared to cisgender men. Those with private (AOR: 0.52, 95% CI 0.33-0.81) or public insurance (AOR: 0.24, 95% CI 0.14-0.40) were less likely to still be on PrEP at ≥1 month compared to those with no insurance.
This study shows that PrEP prescribing can successfully occur at a safety-net, public STI clinic with a high volume of persons of color and underinsured. The model of direct, immediate, and costless provision of initial medication with on-site enrollment in drug assistance programs could be responsible for increased uptake among uninsured individuals. The addition of a PrEP Case Manager to provide systematic appointment reminders, follow up for missed appointments, and linkage to additional services (e.g., gender-affirming therapy) might be beneficial, especially for youth, cisgender women, and transgender women. Reasons for stopping PrEP should routinely be collected and assessed.